After 2000's boom, which brought about a nearly hysterical financial ride for the industry, almost anything would have looked worse. Investors sniffing big profits down the road had jumped aboard the human genome-mapping bandwagon in 2000 with dot-commish glee, which sent valuations rocketing to heights that caused seasoned observers to shake their heads. Read More
